WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer 30 January 2023
Bayer to accelerate drug discovery with Google Cloud's high-performance compute power 12 January 2023
NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs 10 January 2023
Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics 20 December 2022
Bayer launches industry-first public database listing company's science collaborations and partnerships in the U.S. 09 December 2022
Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros 02 December 2022
Vividion Therapeutics names Jenna Goldberg as Chief Medical Officer 09 November 2022
Bayer with continued strong performance 08 November 2022
Bayer signs grant agreement to advance innovation in non-hormonal contraception 20 October 2022
Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage" 18 August 2022
Bayer Consumer Health leaders propose new principles for science-led self-care 02 August 2022
Bayer to sell men's health product Nebido™ to Grünenthal 18 July 2022
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology 29 June 2022
Bayer delivers on medical innovation fueling transformation of pharma business 21 February 2022
Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing 25 January 2022
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog 10 January 2022
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics 10 August 2021
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease 08 June 2021
Bayer to manufacture mRNA vaccine in Germany 01 February 2021
Bayer transforms pharma business through breakthrough innovation in healthcare 14 January 2021
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Tahmeena

Business & Industry

  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed

Research & Development

  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Bayer
  4. CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.